Resources Repository
-
ArticlePublication 2011Cost-Effectiveness of Psychotherapy for Cluster C Personality Disorders
This article, published in the Journal of Clinical Psychiatry, describes a probabilistic Markov cohort model …
This article, published in the Journal of Clinical Psychiatry, describes a probabilistic Markov cohort model that compares the cost-effectiveness of five treatment modalities (long-term outpatient psychotherapy, short-term and long-term day hospital psychotherapy, and short-term and long-term inpatient psychotherapy) for patients with cluster C personality disorders. The analyses are conducted from the societal and payer perspectives. Patient-level data comes from 466 patients with cluster C personality disorders who were admitted to 6 specialist centers of psychotherapy…
State-Transition | Mental Health | Cost-Effectiveness Analysis | Health/Medicine | Europe -
ArticlePublication 2010Cost-Effectiveness of Psychotherapy for Cluster B Personality Disorders
This article, published in the British Journal of Psychiatry, presents a probabilistic Markov cohort model …
This article, published in the British Journal of Psychiatry, presents a probabilistic Markov cohort model that compares the cost-effectiveness of three treatment strategies (outpatient, day-hospital and inpatient psychotherapy) for patients with cluster B personality disorders. Patient-level data is used to populate the model and the analyses are conducted from the societal and payer perspectives. From the societal perspective, the findings show that the incremental cost-effectiveness ratio (ICER) of day hospital psychotherapy compared to outpatient psychotherapy…
State-Transition | Mental Health | Cost-Effectiveness Analysis | Health/Medicine | Europe -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Mathematical Models | Environmental Health | Priority Setting/Ethics | Evidence Synthesis | Technology Assessment | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | North America